14 completed, 8 terminated, 1 recruiting, 1 unknown. 16 Phase 1, 11 Phase 2, 3 Early Phase 1, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 10, Terminated 5, Unknown 1 |
| Phase 2 | 11 | Completed 7, Terminated 3, Unknown 1 |
| Early Phase 1 | 3 | Terminated 2, Completed 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
Follow Craig L Slingluff, Jr: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Excision of Lymph Node Trial (EXCILYNT) (Mel69) Excision of clinically detected lymph node metastasis before any systemic therapy, Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy - Melanoma | Not applicable | Recruiting | Craig L Slingluff, Jr | 66 | 2023-09-06 | 2025-09-17 |
| Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) 6MHP, NeoAg-mBRAF, PolyICLC - Melanoma, Ocular Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 22 | 2020-09-28 | 2024-07-16 |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors Echopulse, Poly ICLC, Standard of Care PD-1 Therapy - Melanoma, Breast Cancer | Phase 1 | Terminated | Craig L Slingluff, Jr | 5 | 2019-11-21 | 2025-07-14 |
| Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma 6MHP, Montanide ISA-51, polyICLC - Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 33 | 2018-11-13 | 2024-02-06 |
| Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab 6MHP, Pembrolizumab - Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 22 | 2016-10-06 | 2023-08-25 |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib BRAF inhibitor, 6MHP, MEK inhibitor - Melanoma | Early Phase 1 | Terminated | Craig L Slingluff, Jr | 8 | 2016-04-01 | 2023-12-12 |
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma 6MHP, Montanide ISA-51, polyICLC - Melanoma | Phase 1 / Phase 2 | Terminated | Craig L Slingluff, Jr | 48 | 2015-05-12 | 2023-10-30 |
| A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma Ipilimumab, 6MHP - Melanoma | Phase 1 / Phase 2 | Terminated | Craig L Slingluff, Jr | 3 | 2015-04-01 | 2020-05-05 |
| Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer Pembrolizumab, Neoadjuvant Chemoradiation - Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Craig L Slingluff, Jr | 68 | 2015-03-01 | 2021-08-13 |
| Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, Resiquimod - Melanoma, Metastatic Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 50 | 2014-05-01 | 2024-02-28 |
| Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies pBCAR3-phosphopeptide, pIRS2-phosphopeptide, 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide) - Melanoma | Phase 1 | Completed | Craig L Slingluff, Jr | 15 | 2013-05-01 | 2016-08-12 |
| A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS), MELITAC 12.1 + Montanide ISA-51 + polyICLC - Melanoma | Phase 1 | Completed | Craig L Slingluff, Jr | 53 | 2012-10-01 | 2016-08-12 |
| Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer poly-ICLC, 9 Peptides from Her-2/neu, CEA, & CTA, Peptide-tet - Breast Cancer | Phase 1 | Terminated | Craig L Slingluff, Jr | 11 | 2012-07-01 | 2020-05-08 |
| Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI recMAGE-A3 + AS15 ASCI - Melanoma | Early Phase 1 | Completed | Craig L Slingluff, Jr | 25 | 2011-06-01 | 2016-04-04 |
| Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1 - Melanoma | Phase 1 | Terminated | Craig L Slingluff, Jr | 11 | 2009-11-01 | 2016-12-16 |
| Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer 9 Peptides from Her-2/neu, CEA, & CTA - Breast Neoplasms | Phase 1 | Completed | Craig L Slingluff, Jr | 9 | 2009-05-01 | 2016-12-16 |
| Vaccine Therapy in Treating Patients With Advanced Melanoma incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide - Intraocular Melanoma, Malignant Conjunctival Neoplasm | Phase 1 | Completed | Craig L Slingluff, Jr | 45 | 2008-05-01 | 2016-12-16 |
| Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine, tetanus toxoid helper peptide, carboplatin - Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Terminated | Craig L Slingluff, Jr | 6 | 2006-04-13 | 2022-09-21 |
| Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine - Melanoma (Skin) | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 170 | 2005-03-01 | 2021-04-20 |
| Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim - Melanoma (Skin) | Phase 1 | Completed | Craig L Slingluff, Jr | 2004-11-04 | 2020-03-27 |
Showing 20 of 24. Sign in to see all of them.
Melanoma (19) · Breast Neoplasms (3) · Ovarian Neoplasms (2) · Uveal Melanoma (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Neoplasms (1) · Neoplasms, Squamous Cell (1)
incomplete Freund's adjuvant (4) · montanide ISA 51 (3) · Cyclophosphamide (2) · Receptor Protein-Tyrosine Kinases (2) · pembrolizumab (2) · poly ICLC (2) · sargramostim (2) · Biopsy (1) · Carboplatin (1) · Chemotherapy, Adjuvant (1) · Dimethyl Sulfoxide (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · High-Intensity Focused Ultrasound Ablation (1) · Imiquimod (1) · Ipilimumab (1)
United States (24)
Craig L. Slingluff, Jr., MD (6) · Craig L Slingluff, MD (4) · Craig L. Slingluff, MD (4) · Craig L Slingluff, Jr., MD (2) · Elizabeth Gaughan, MD (2) · Charles M. Friel, MD (1) · Craig L Slingluff, Jr., M.D. (1) · Craig L. Slingluff, M.D. (1) · David R. Brenin, M.D. (1) · Lynn Dengel, MD, MSc (1) · Osama Rahma, MD (1) · Patrick M Dillon, MD (1) · Victor Engelhard, PhD (1)
PMID 32350119, PMID 20727190, PMID 21690475, PMID 23197414, PMID 24377099, PMID 26581199, PMID 29157306, PMID 31248461, PMID 32385144, PMID 32819975, PMID 34413169, PMID 36746511, PMID 40536492, PMID 41775435
R01CA178846 (2), P30CA044579 (1), R01CA057653 (1), R21CA130340 (1)